CD8A and neoplasm: Specifically, B, DC, Th1, CD8+ T, activated NK, gamma delta T cells, and M1 macrophages with ability to directly or indirectly kill abnormal tumor cells (48–50) might support better prognosis in low-stemness subtypes.